FY2028 EPS Estimates for REGENXBIO Raised by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Leerink Partnrs increased their FY2028 earnings estimates for shares of REGENXBIO in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings per share of ($2.58) for the year, up from their previous forecast of ($2.59). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share.

RGNX has been the topic of a number of other reports. Chardan Capital reiterated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a report on Monday, June 9th. The Goldman Sachs Group reduced their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Price Performance

Shares of RGNX stock opened at $8.16 on Monday. The company has a market capitalization of $409.31 million, a price-to-earnings ratio of -2.62 and a beta of 1.06. REGENXBIO has a one year low of $5.04 and a one year high of $15.36. The company's fifty day moving average price is $8.96 and its 200-day moving average price is $7.95.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative net margin of 100.62% and a negative return on equity of 53.29%.

Insider Buying and Selling at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director directly owned 475,103 shares in the company, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 12.79% of the stock is currently owned by company insiders.

Institutional Trading of REGENXBIO

A number of large investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC increased its holdings in shares of REGENXBIO by 78.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 30,630 shares of the biotechnology company's stock worth $268,000 after buying an additional 13,458 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of REGENXBIO by 67.1% in the 2nd quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company's stock worth $143,000 after buying an additional 6,992 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of REGENXBIO in the 1st quarter worth about $1,123,000. Jane Street Group LLC increased its holdings in shares of REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company's stock worth $2,961,000 after buying an additional 249,156 shares during the last quarter. Finally, Exome Asset Management LLC bought a new stake in shares of REGENXBIO in the 1st quarter worth about $2,898,000. 88.08% of the stock is currently owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.